A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Bioavailability of Branebrutinib in a Tablet Formulation Relative to Branebrutinib (RBA) in a Capsule Formulation Including the Effect of Food (Low-fat/Low-calorie and a High-fat/High-calorie) on the Bioavailability of Branebrutinib From a Tablet Formulation and a Double-blind Study to Evaluate the Safety and Pharmacokinetics of Branebrutinib From a Tablet Formulation in a Multiple-dose Arm in Healthy Participants

The purpose of this study is to assess the relative bioavailability of branebrutinib tablet formulation relative to the capsule formulation in order to identify doses that would provide exposures similar to the capsule formulation over the dose range that may be used in future clinical studies, evaluate the effect of food on the bioavailability of branebrutinib from a tablet formulation at a dose projected to provide similar pharmacokinetics (PK) as the 9 mg capsule formulation, and evaluate the safety and the PK of multiple oral dose of tablet formulation of branebrutinib in healthy participants.

Start Date08 Apr 2022

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT05014438

/ CompletedPhase 2

A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.

Start Date17 Aug 2021

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT04515628

/ CompletedPhase 1

An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State Branebrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

The purpose of this study is to examine the interaction of branebrutinib with rosuvastatin. Rosuvastatin is a substrate of the breast cancer resistance protein (BCRP) transporter, which has a drug level profile that can be markedly altered by coadministration of known inhibitors of the BCRP transporter. With widespread use of statins as cholesterol-lowering agents, rosuvastatin is also a likely concomitant drug for participants who would potentially be treated with branebrutinib.

Start Date02 Aug 2020

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Branebrutinib

100 Translational Medicine associated with Branebrutinib

100 Patents (Medical) associated with Branebrutinib

Literatures (Medical) associated with Branebrutinib

09 May 2024·Journal of Medicinal Chemistry

Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist

Article

Author: Raux, Brigitt ; Elkins, Jonathan M. ; Huber, Kilian V. M. ; Seupel, Raina ; Sloman, David L. ; Rogers, Catherine ; Fedorov, Oleg ; Simelis, Klemensas ; Ward, Jennifer ; Marques, Anne-Sophie M. C. ; Bennett, James ; Balıkçı, Esra ; Bauer, Ludwig G. ; Schützenhofer, Kira ; Ahel, Ivan ; Szommer, Tamas ; Cheng, Carol ; Singh, Usha ; Buchan, Karly ; Brennan, Paul E.

Cofactor mimicry represents an attractive strategy for the development of enzyme inhibitors but can lead to off-target effects due to the evolutionary conservation of binding sites across the proteome. Here, we uncover the ADP-ribose (ADPr) hydrolase NUDT5 as an unexpected, noncovalent, off-target of clinical BTK inhibitors. Using a combination of biochemical, biophysical, and intact cell NanoBRET assays as well as X-ray crystallography, we confirm catalytic inhibition and cellular target engagement of NUDT5 and reveal an unusual binding mode that is independent of the reactive acrylamide warhead. Further investigation of the prototypical BTK inhibitor ibrutinib also revealed potent inhibition of the largely unstudied NUDIX hydrolase family member NUDT14. By exploring structure-activity relationships (SARs) around the core scaffold, we identify a potent, noncovalent, and cell-active dual NUDT5/14 inhibitor. Cocrystallization experiments yielded new insights into the NUDT14 hydrolase active site architecture and inhibitor binding, thus providing a basis for future chemical probe design.

23 Mar 2023·Journal of Medicinal ChemistryQ1 · MEDICINE

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases

Q1 · MEDICINE

Article

Author: Shi, Gongyin ; Wei, Min ; Wang, Lai ; Zhao, Yuan ; Guo, Ying ; Tian, Alice ; Yuan, Xi ; Liu, Ye ; Wei, Qiang ; Guo, Yunhang ; Sun, Xuebing ; Young, Steve ; Guo, Yin ; Li, Yong ; Song, Xiaomin ; Xin, Lei ; Luo, Lusong ; Zhang, Wei ; Liu, Junhua ; Li, Xin ; Wu, Yue ; Yu, Desheng ; Su, Dan ; Wang, Zhiwei ; Sun, Hanzi ; Zhang, Cuining ; Cheng, Zhenzhen ; Hu, Nan ; Zhang, Shuo ; He, Min ; Zhang, Taichang ; Wang, Fan ; Zhou, Changyou ; Chen, Shuaishuai ; Xing, Haimei ; Zhang, Jiye ; Yin, Longbo ; Liu, Xuesong ; Zhou, Xing ; Zhang, Bo

Bruton's tyrosine kinase (BTK) plays an essential role in B-cell receptor (BCR)-mediated signaling as well as the downstream signaling pathway for Fc receptors (FcRs). Targeting BTK for B-cell malignancies by interfering with BCR signaling has been clinically validated by some covalent inhibitors, but suboptimal kinase selectivity may lead to some adverse effects, which also makes the clinical development of autoimmune disease therapy more challenging. The structure-activity relationship (SAR) starting from zanubrutinib (BGB-3111) leads to a series of highly selective BTK inhibitors, in which BGB-8035 is located in the ATP binding pocket and has similar hinge binding to ATP but exhibits high selectivity over other kinases (EGFR, Tec, etc.). With an excellent pharmacokinetic profile as well as demonstrated efficacy studies in oncology and autoimmune disease models, BGB-8035 has been declared a preclinical candidate. However, BGB-8035 showed an inferior toxicity profile compared to that of BGB-3111.

15 Apr 2022·Organic Process Research & Development

Leveraging High-Throughput Experimentation to Drive Pharmaceutical Route Invention: A Four-Step Commercial Synthesis of Branebrutinib (BMS-986195)

Author: Skliar, Dimitri ; Forest, Robert V. ; Steinhardt, Sarah E. ; Guerrero, Carlos A. ; Lou, Sha ; Simmons, Eric M. ; Borovika, Alina ; Geng, Peng ; Strotman, Neil A. ; Tan, Yichen ; Stevens, Jason M. ; Fan, Junying

The invention of a com. route to the Bruton kinase inhibitor branebrutinib (BMS-986195) in four total chem. steps was described.The execution of high-throughput experimentation (HTE) coupled with a first-principles approach across the proposed synthetic route enabled the identification of a novel indolization reaction that rapidly generated high synthetic complexity, as the centerpiece of the synthesis.A parallel HTE strategy during route design enabled the efficient and rapid evaluation of multiple options within a short timeframe to complete rigorous process development while mitigating the risks associated with implementing new chem. featuring an aggressive disconnection strategy.

News (Medical) associated with Branebrutinib

02 Feb 2023

·www.fiercebiotech.com

BMS knocks down a handful of early cancer candidates amid pipeline cleanout

Bristol Myers Squibbs' pipeline cuts come as the company expects to keep R&D spending at 2022 levels. Bristol Myers Squibb is taking a broom to the bottom of its pipeline, axing at least nine assets including one phase 2 med being studied in a variety of solid tumors. The cleanout was disclosed in the company’s fourth-quarter earnings release Thursday morning, providing an updated glimpse of the company’s early-stage plans. All told the company cut six cancer prospects, including a phase 2 anti-CTLA4 candidate, one fibrosis candidate and two immunology assets. Most of the cancer prospects were phase 1-level solid tumor prospects, including a STING agonist, IL-12 F, SIRPα antagonist and the anti-CTLA4 med. But BMS also whittled down its blood cancer prospects as well, ending development of a ROR CAR-T therapy that was in phase 1. Following behind the line of axed cancer meds is branebrutinib, an immunology asset that finished up a phase 2 trial in patients with lupus, primary Sjögren's syndrome and rheumatoid arthritis. Patients with RA also received BMS’s approved med Orencia in an open-label follow-up portion. An update to the clinical trial record in December showed that the study jumped from recruiting to completed. Another mid-stage immunology option, an MK2 inhibitor to treat ankylosing spondylitis, was culled as well. The move to wipe away nearly 10 assets comes as the company has projected that R&D spending in the new year will be in line with 2022, which was roughly $9.5 billion. BMS also expanded on a recent decision to terminate a phase 2 trial of the company’s anti-TIGIT med, BMS-986207, as part of a triple combination therapy with Yervoy and Opdivo due to safety reasons. Chief Medical Officer Samit Hirawat, M.D., said that toxicity was observed when tacked onto the immuno-oncology combo. Hirawat promised more data and specifics on what happened with the triple-combo, "but because of those safety reasons, we have decided to terminate this particular trial at this time.” The decision pours additional cold water onto the anti-TIGIT class of immunotherapies, once-thought to be a rising star to replace the current generation of checkpoint inhibitors. But disappointing readouts from Roche last year made others reconsider their bets. Still, companies like Gilead, Novartis and GSK are pressing ahead as Roche waits for critical overall survival data.

Phase 2ImmunotherapyDrug ApprovalClinical Trial FailurePhase 1

02 Feb 2023

·endpts.com

The Big Pharma axe: Merck cuts chikungunya vax, Bristol Myers drops CytomX-partnered programs, and more

As fourth quarter earnings come in, Big Pharmas are disclosing changes to their pipelines during their investor calls, and sometimes more quietly in presentation appendices. Merck dropped its chikungunya vaccine candidate, which completed a Phase II study. Merck acquired the vaccine through its purchase of Themis Bioscience in 2020. In developing a vaccine for chikungunya, a mosquito-borne virus, Valneva is the frontrunner, as it submitted its vaccine to the FDA at the end of December. Merck didn’t mention this vaccine cut in its call, instead choosing to highlight its work on a Dengue vaccine candidate. The pharma company is partnering with the Instituto Butantan in Brazil on its dengue vaccine candidate, separate from its own vaccine. “We are collaborating with a team there to conduct a detailed analysis of these positive topline phase three results to determine next steps for our own dengue vaccine candidate V181, currently in phase two development. Merck’s goal is to make V181 available outside of Brazil for populations at risk for dengue,” EVP of Merck Research Laboratories Dean Li said. Merck also dropped a glioblastoma indication for Lenvima, which it had been studying in combination with Keytruda for its LEAP program. In an email, Merck told Endpoints News , “As part of our routine pipeline prioritization Merck has elected to discontinue both programs.” Bristol Myers Squibb made a number of culls — most notably two programs from its CytomX partnership on developing CTLA-4 antibodies. One of those two was a “peptide masked” version of the Yervoy, Bristol Myers’ checkpoint inhibitor that blocks CTLA-4. That candidate is still continuing in a separate Phase II solid tumors program. In addition, during its investor call, Bristol Myers said it was stopping development on its atopic dermatitis antibody cendakimab, which recently completed a Phase II study, according to clinical trials.gov . CMO Samit Hirawat commented, “In atopic dermatitis, there are several therapies that have recently become available for patients and they’re very effective. And so we had set our threshold quite high in terms of making that difference for the patients for atopic dermatitis. “So, we have seen the data, we do meet the primary endpoint, but we don’t think that it has a competitive advantage over what is available to the patients at this time,” Hirawat continued. Bristol Myers also terminated a Phase I trial for an anti-TIGIT drug in combination with immunotherapy due to toxicity issues. Hirawat said more details would be presented at a future conference. And according to its presentation, the Big Pharma cut BTK inhibitor branebrutinib, which it was studying in autoimmune diseases; an MK2 inhibitor for ankylosing spondylitis, a type of arthritis; as well as a Phase I STING agonist, among other early-stage programs. Eli Lilly and Takeda also made a handful early-stage changes, with Lilly dropping a Phase I candidate for diabetes and NASH, and Takeda cutting one for nausea and vomiting (where it still has another experimental drug in Phase I as well). Nicole DeFeudis and Beth Bulik contributed reporting.

Phase 2VaccinePhase 1AcquisitionImmunotherapy

09 Jan 2023

·www.prnewswire.com

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Aclaris Therapeutics [Zunsemetinib (ATI-450)], Abivax [ABX464], and others with their key candidates are in the late clinical and filing stage. LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Rheumatoid Arthritis Market Report As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021. According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4. 7 million in 2021. Leading rheumatoid arthritis companies such as Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others are developing novel rheumatoid arthritis drugs that can be available in the rheumatoid arthritis market in the coming years. The promising rheumatoid arthritis therapies in the pipeline include Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others. In June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA. In December 2021, Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research. Discover which therapies are expected to grab the major rheumatoid arthritis market share @ Rheumatoid Arthritis Market Report Rheumatoid Arthritis Overview Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown. Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis. There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs). Rheumatoid Arthritis Epidemiology Segmentation DelveInsight estimates that there were approximately 4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021. Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021 The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases Total Diagnosed Prevalent Cases Gender-specific Prevalent Cases Age-specific Prevalent Cases Severity-specific Prevalent Cases Patients on Targeted Therapies Line-Wise Treated Cases Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights Rheumatoid Arthritis Treatment Market Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression. Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment. Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive. To know more about rheumatoid arthritis guidelines, visit @ Rheumatoid Arthritis Management Rheumatoid Arthritis Pipeline Therapies and Key Companies Artlegia (Olokizumab): R-Pharm TS-152 (Ozoralizumab): Taisho Pharmaceuticals Otilimab (GSK3196165/MOR103): GlaxoSmithKline ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics Branebrutinib: Bristol Myers Squibb LY3462817: Eli Lilly and Company TAS5315: Taiho Pharmaceutical Rabeximod (Rob 803): Cyxone GS-5718: Gilead Sciences KPL-404: Kiniksa Pharmaceuticals MBS2320: Istesso AMT-101: Applied Molecular Transport Dazodalibep (HZN-4920): Horizon Therapeutics Cevidoplenib (SKI-O-703): Genosco/Oscotec HB-AdMSCs: Hope Biosciences ABX464: Abivax MPC-300-IV: Mesoblast PF-06650833: Pfizer JTE 051: Akros Pharma/Japan Tobacco Dekavil (F8IL10): Pfizer/Philogen ABBV-154: AbbVie PF-06651600 (Ritlecitinib): Pfizer AP1189: SynAct Pharma Learn more about the FDA-approved drugs for rheumatoid arthritis @ Drugs for Rheumatoid Arthritis Treatment Rheumatoid Arthritis Market Dynamics The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth. Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as JAKi and the upcoming BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA. However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market. In addition, the entry of biosimilars has already begun in the US and EU (i.e., Remicade biosimilars), and as a result, sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as Humira (i.e., 2023 in the US), Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market. Scope of the Rheumatoid Arthritis Market Report Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement Discover more about rheumatoid arthritis drugs in development @ Rheumatoid Arthritis Clinical Trials Table of Contents Related Reports Rheumatoid Arthritis Epidemiology Forecast Rheumatoid Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Juvenile Rheumatoid Arthritis Pipeline Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Juvenile Rheumatoid Arthritis Market Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Psoriatic Arthritis Market Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market Related Healthcare Blogs Rheumatoid Arthritis Emerging Drugs Knee Osteoarthritis Pipeline Rheumatoid Arthritis Market Scenario Juvenile Idiopathic Arthritis Therapy Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Clinical Result

100 Deals associated with Branebrutinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11478	-	-	DB15347

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Sjögren's syndrome	Phase 3	France	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Argentina	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Belgium	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Mexico	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Germany	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Poland	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Netherlands	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	Spain	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	United States	Bristol Myers Squibb Co.	07 Jan 2020
Primary Sjögren's syndrome	Phase 3	United Kingdom	Bristol Myers Squibb Co.	07 Jan 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04186871 (CTgov)	Phase 2	Systemic Lupus Erythematosus \| Primary Sjögren's syndrome	119	placebo (SLE- Placebo)	obpadzqfxy(sxcdahkqmz) = rdlbnvxble zuoahsjctz (lwnyoxslbf, fjpzarmuwx - ddaopkqnhw) View more	-	16 Jan 2024
NCT04186871 (CTgov)	Phase 2	Systemic Lupus Erythematosus \| Primary Sjögren's syndrome	119	Branebrutinib (SLE- Branebrutinib)	obpadzqfxy(sxcdahkqmz) = qyplqhviwd zuoahsjctz (lwnyoxslbf, geyradcutm - qettirjmdg) View more	-	16 Jan 2024
NCT05014438 (CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	17	Placebo	mcmrjyzeao(jsodvafcyw) = rrecbokpsm aqczqyrzyj (tgsfabpmtt, hvbpoeqgyu - auumaghpjb) View more	-	18 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis